ipid profiles of HIV-infected patients with dyslipidemia after switching from efavirenz to dolutegravir

Khon Kaen university0 个研究点目标入组 64 人开始时间: 2022年11月18日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•This is a prospective, open-label, cohort study in HIV-1 infected adults aged more than18 years who have undergone at least six months of EFV-based therapy, have HIV-1 RNA levels less than 50 copies/mL for more than 6 months before switching, and are diagnosed with dyslipidemia or have risk factors for atherosclerosis cardiovascular disease (ASCVD) based on modified National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines.

•Exclusion criteria are pregnancy or breastfeeding, active opportunistic infections, or taking metformin more than 1,000 mg/day, rifampicin, St. john's wort, antiarrhythmic drugs (e.g., dofetilide, pilsicainide), antiepileptic drugs (e.g., carbamazepine, oxcarbazepine, phenytoin, phenobarbital), or medications or supplements containing polyvalent cations (e.g., magnesium, aluminum, cation-containing antacids or laxatives, sucralfate, buffered medications).

发起方